Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 151 No. 0708 (2021)

Adherence to, and patient convenience of, prolonged-release tacrolimus in stable kidney and liver transplant recipients after conversion from immediate-release tacrolimus in routine clinical practice in Switzerland

DOI
https://doi.org/10.4414/smw.2021.20453
Cite this as:
Swiss Med Wkly. 2021;151:w20453
Published
18.02.2021

Summary

AIMS OF THE STUDY

Non-adherence to immunosuppressive therapy in patients following solid organ transplantation is associated with an increased risk of transplant rejection and graft loss. A high pill burden can adversely affect patients’ implementation of their treatment regimens and may lead to omitting doses of medication. The aim of this study was to investigate medication implementation adherence in liver and kidney transplant recipients converted from twice-daily, immediate-release tacrolimus to once-daily, prolonged-release tacrolimus.

METHODS

This multicentre, non-interventional, observational, 12-month study evaluated implementation adherence in routine practice at five hospitals in Switzerland. Patients attended four clinical visits: at baseline (pre-conversion), and then at week 2, month 6 and month 12 post-conversion. Implementation was defined as consistently taking medication at the correct time and at the correct dose in order to achieve target tacrolimus trough levels. Implementation adherence was evaluated in three ways: using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) interview questionnaire (at baseline and month 12), investigator-rated patient adherence (recorded at all visits), and tacrolimus trough levels (assessed throughout the study; sub-therapeutic levels were predefined by the investigator on an individual patient basis, over-therapeutic levels were defined as tacrolimus trough levels >15 ng/ml). The primary composite endpoint was non-adherence according to the BAASIS at month 12, any post-conversion investigator adherence rating of “poor”, or sub-therapeutic or over-therapeutic tacrolimus trough levels at month 6 or 12. Secondary endpoints included: individual components of the composite non-adherence primary endpoint, tacrolimus pill burden, patient satisfaction, and adverse drug reactions.

RESULTS

Seventy-five patients received prolonged-release tacrolimus; 68 patients (46 kidney and 22 liver transplant recipients) completed the study. Of these 68 patients, 24 had missing data for at least one component of the primary endpoint; therefore, data for the primary composite endpoint were evaluable for 44 patients. Most (81.8%; 36/44) patients were non-adherent for the composite endpoint. Sub-therapeutic tacrolimus trough levels outside of the predefined therapeutic range were the largest contributor to the composite endpoint, and were detected in 62.0% (31/50) of patients. Overall non-adherence according to the BAASIS was similar pre-conversion (30.7%) and at 12 months post-conversion (28.3%). Investigators rated adherence as “poor” for two patients. Prolonged-release tacrolimus decreased tacrolimus pill burden in 66.7% of patients. All patients were very satisfied / satisfied with prolonged-release tacrolimus; 75.0% found it easier to remember to take prolonged-release versus immediate-release tacrolimus. Twenty percent of patients reported adverse drug reactions, with infections being the most frequently reported (9.3%).

CONCLUSION

Overall, 1-year non-adherence rates were similar following conversion from immediate-release to prolonged-release tacrolimus; however, prolonged-release tacrolimus intake was more convenient. No new safety signals were detected.

References

  1. Beckebaum S, Iacob S, Sweid D, Sotiropoulos GC, Saner F, Kaiser G, et al. Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int. 2011;24(7):666–75. doi:.https://doi.org/10.1111/j.1432-2277.2011.01254.x
  2. Vasquez EM, Tanzi M, Benedetti E, Pollak R. Medication noncompliance after kidney transplantation. Am J Health Syst Pharm. 2003;60(3):266–9. doi:.https://doi.org/10.1093/ajhp/60.3.266
  3. Sellarés J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12(2):388–99. doi:.https://doi.org/10.1111/j.1600-6143.2011.03840.x
  4. Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant. 2015;15(11):2921–30. doi:.https://doi.org/10.1111/ajt.13347
  5. Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Hanson L, Roth D, et al. Graft failure due to noncompliance among 628 kidney transplant recipients with long-term follow-up: a single-center observational study. Transplantation. 2014;97(9):925–33. doi:.https://doi.org/10.1097/01.TP.0000438199.76531.4a
  6. Lieber SR, Volk ML. Non-adherence and graft failure in adult liver transplant recipients. Dig Dis Sci. 2013;58(3):824–34. doi:.https://doi.org/10.1007/s10620-012-2412-0
  7. Kuypers DRJ, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, et al.; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013;95(2):333–40. doi:.https://doi.org/10.1097/TP.0b013e3182725532
  8. Chapman JR. Compliance: the patient, the doctor, and the medication? Transplantation. 2004;77(5):782–6. doi:.https://doi.org/10.1097/01.TP.0000110411.23547.D4
  9. Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group. Transplantation. 2017;101(4S, Suppl 2):S1–56. doi:.https://doi.org/10.1097/TP.0000000000001651
  10. Morales JM, Varo E, Lázaro P. Immunosuppressant treatment adherence, barriers to adherence and quality of life in renal and liver transplant recipients in Spain. Clin Transplant. 2012;26(2):369–76. doi:.https://doi.org/10.1111/j.1399-0012.2011.01544.x
  11. Hart A, Smith JM, Skeans MA, Gustafson SK, Wilk AR, Castro S, et al. OPTN/SRTR 2018 Annual Data Report: Kidney. Am J Transplant. 2020;20(Suppl s1):20–130. doi:.https://doi.org/10.1111/ajt.15672
  12. Kwong A, Kim WR, Lake JR, Smith JM, Schladt DP, Skeans MA, et al. OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant. 2020;20(Suppl s1):193–299. doi:.https://doi.org/10.1111/ajt.15674
  13. Trunečka P, Boillot O, Seehofer D, Pinna AD, Fischer L, Ericzon B-G, et al.; Tacrolimus Prolonged Release Liver Study Group. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010;10(10):2313–23. doi:.https://doi.org/10.1111/j.1600-6143.2010.03255.x
  14. Albano L, Banas B, Klempnauer JL, Glyda M, Viklicky O, Kamar N ; Optimising immunoSuppression After Kidney transplantation with ADVAGRAF Study Group. OSAKA trial: a randomized, controlled trial comparing tacrolimus QD and BD in kidney transplantation. Transplantation. 2013;96(10):897–903. doi:.https://doi.org/10.1097/TP.0b013e3182a203bd
  15. Astellas Pharma Europe Ltd. Summary of Product Characteristics: Advagraf 0.5mg, 1mg, 3mg and 5mg prolonged-release hard capsules. [Internet]. 2019 [cited 2019 Sep 19]. Available from: https://www.medicines.org.uk/emc/product/345/smpc
  16. De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Ann Intern Med. 2018;169(1):30–5. doi:.https://doi.org/10.7326/M18-0543
  17. Dobbels F, Berben L, De Geest S, Drent G, Lennerling A, Whittaker C, et al.; Transplant360 Task Force. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90(2):205–19. doi:.https://doi.org/10.1097/TP.0b013e3181e346cd
  18. Harrell FE, Dupont C, et al. Hmisc: Harrell miscellaneous. R package version 3.16-0. [Internet]. 2015. Available from: http://cran.microsoft.com/snapshot/2015-07-13/web/packages/Hmisc/index.html
  19. Vlaminck H, Maes B, Evers G, Verbeke G, Lerut E, Van Damme B, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant. 2004;4(9):1509–13. doi:.https://doi.org/10.1111/j.1600-6143.2004.00537.x
  20. Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation. 2004;77(5):769–76. doi:.https://doi.org/10.1097/01.TP.0000110408.83054.88
  21. Rodrigue JR, Nelson DR, Hanto DW, Reed AI, Curry MP. Patient-reported immunosuppression nonadherence 6 to 24 months after liver transplant: association with pretransplant psychosocial factors and perceptions of health status change. Prog Transplant. 2013;23(4):319–28. doi:.https://doi.org/10.7182/pit2013501
  22. Dew MA, DiMartini AFA, De Vito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83(7):858–73. doi:.https://doi.org/10.1097/01.tp.0000258599.65257.a6
  23. Chisholm-Burns M, Pinsky B, Parker G, Johnson P, Arcona S, Buzinec P, et al. Factors related to immunosuppressant medication adherence in renal transplant recipients. Clin Transplant. 2012;26(5):706–13. doi:.https://doi.org/10.1111/j.1399-0012.2011.01589.x
  24. Tielen M, van Exel J, Laging M, Beck DK, Khemai R, van Gelder T, et al. Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: a 2-year follow-up study. J Transplant. 2014;2014:675301. doi:.https://doi.org/10.1155/2014/675301
  25. Schmid-Mohler G, Thut MP, Wüthrich RP, Denhaerynck K, De Geest S. Non-adherence to immunosuppressive medication in renal transplant recipients within the scope of the Integrative Model of Behavioral Prediction: a cross-sectional study. Clin Transplant. 2010;24(2):213–22. doi:.https://doi.org/10.1111/j.1399-0012.2009.01056.x
  26. Lehner LJ, Reinke P, Hörstrup JH, Rath T, Suwelack B, Krämer BK, et al. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: a multicenter, noninterventional study. Clin Transplant. 2018;32(1):13142. doi:.https://doi.org/10.1111/ctr.13142
  27. Tanzi MG, Undre N, Keirns J, Fitzsimmons WE, Brown M, First MR. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. Clin Transplant. 2016;30(8):901–11. doi:.https://doi.org/10.1111/ctr.12763
  28. Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc. 1999;31(1–2):296–8. doi:.https://doi.org/10.1016/S0041-1345(98)01633-9
  29. Dharancy S, Giral M, Tetaz R, Fatras M, Dubel L, Pageaux G-P. Adherence with immunosuppressive treatment after transplantation: results from the French trial PREDICT. Clin Transplant. 2012;26(3):E293–9. doi:.https://doi.org/10.1111/j.1399-0012.2012.01652.x
  30. van Boekel GAJ, Kerkhofs CHH, Hilbrands LB. Treatment satisfaction in renal transplant patients taking tacrolimus once daily. Clin Ther. 2013;35(11):1821–9.e1. doi:.https://doi.org/10.1016/j.clinthera.2013.09.014
  31. Sabbatini M, Garofalo G, Borrelli S, Vitale S, Torino M, Capone D, et al. Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study. Patient Prefer Adherence. 2014;8:73–81. doi:.https://doi.org/10.2147/PPA.S54922
  32. Ichimaru N, Kakuta Y, Abe T, Okumi M, Imamura R, Isaka Y, et al. Treatment adherence in renal transplant recipients: a questionnaire survey on immunosuppressants. Transplant Proc. 2008;40(5):1362–5. doi:.https://doi.org/10.1016/j.transproceed.2008.02.083
  33. Guirado L, Cantarell C, Franco A, Huertas EG, Fructuoso AS, Fernández A, et al.; GREAT Study Group. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant. 2011;11(9):1965–71. doi:.https://doi.org/10.1111/j.1600-6143.2011.03571.x
  34. Dumortier J, Guillaud O, Boillot O. Conversion from twice daily tacrolimus to once daily tacrolimus in long-term stable liver transplant recipients: a single-center experience with 394 patients. Liver Transpl. 2013;19(5):529–33. doi:.https://doi.org/10.1002/lt.23638
  35. Sukkha S, Chindavijak B, Montakantikul P, Ingsathit A, Nosoongnoen W, Sumethkul V. Trough level from twice daily to once daily tacrolimus in early conversion kidney transplant recipients: a prospective study. Int J Clin Pharm. 2017;39(6):1298–303. doi:.https://doi.org/10.1007/s11096-017-0549-9
  36. Guirado L, Burgos D, Cantarell C, Fernández A, Franco A, Gentil MA, et al. Medium-term renal function in a large cohort of stable kidney transplant recipients converted from twice-daily to once-daily tacrolimus. Transplant Direct. 2015;1(7):e24. doi:.https://doi.org/10.1097/TXD.0000000000000536
  37. Kim SH, Lee SD, Kim YK, Park S-J. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients. Hepatobiliary Pancreat Dis Int. 2015;14(4):374–9. doi:.https://doi.org/10.1016/S1499-3872(15)60378-2

Most read articles by the same author(s)

<< < 1 2 3